In liver cancer, the FPR2 ligand lipoxin A4 (LXA4) can reduce VEGF secretion and inhibit tumor angiogenesis (Chen et al., 2010), but the role of WKYMVm in liver cancer has not been reported yet. Here, FPR2 is linked to neoplasm.